ALX Oncology(ALXO) - 2023 Q4 - Annual Results

Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., March 7, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. "This past year proved to be a p ...